Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on CSL.
RELATED STOCKHEAD STORIES
Health & Biotech
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
News
Closing Bell: ASX ends Friday in style; NoviqTech explodes 180pc
News
ASX Lunch Wrap: ASX rallies as MinRes admits slip-up; Cyclone doubles after Vale deal
Experts
Hot Money Monday: Why these 12 ASX stocks could score big under Trump’s trade threats
Health & Biotech
Health Check: Which biotech boards are at risk of a ‘second strike’?
Experts
CRITERION: Share valuations look overheated, but it’s a tale of two sectors
Health & Biotech
Scott Power: Which company dropped 30pc on its latest quarterly result?
Health & Biotech
Health Check: Nothing to spook investors in CSL’s update as the blood still flows thick
Health & Biotech
Scott Power: Which ASX health stocks reaffirm FY25 guidance?
Health & Biotech
Scott Power: ASX health stocks rise as focus shifts to reporting season
Health & Biotech
September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Health & Biotech
Broker Upgrades: Earnings season reveals gems, and Telix and CSL are ones to watch
News
ASX Small Caps Lunch Wrap: Markets flat ahead of US rate call. It’s eerily quiet today
Experts
CRITERION: Reporting season shows the good, the bad and the ugly on the ASX
News
ASX Small Caps Weekly Wrap: The ASX bounced back like an exonerated executive this week. Thanks, Wall Street.
News
ScoPo’s Powerplays: ASX health stocks rise as ‘Pro Medicus again hit the ball out of the park’
News
